Company: BDRX
Filing Date: 2025-09-26
Form Type: F-3
Source: 0001214659-25-014255
Chunk: 7

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-26
Form: F-3
Chunk 7
---
 2023, we held our annual general meeting of shareholders,
or June AGM, and our shareholders passed resolutions, among other procedural items, to approve the allotment of, and disapplication of
pre-emption rights in respect of, up to 7.0 billion Ordinary Shares. On June 14, 2023, we also held a separate general meeting of shareholders,
or June GM, and our shareholders passed resolutions to (x)(i) re-designate our deferred shares into A deferred shares, or the Re-Designation,
and (ii) subdivide our Ordinary Shares of £0.02 nominal value each into one ordinary share of £0.001 nominal value and 19
B deferred shares of £0.001 nominal value each, each the Subdivision, and (y) adopt new articles of association, or the Articles
of Association, which made consequential amendments to the existing Articles of Association of the Company to reflect the Re-Designation
and the Subdivision, together with certain other changes to reflect that the Ordinary Shares were no longer admitted to trading on AIM.
As is standard for deferred shares, each B deferred share has very limited rights and is effectively valueless. The B deferred shares
have the rights and restrictions as set out in the Articles of Association and do not entitle the holder thereof to receive notice of
or attend and vote at any general meeting of the Company or to receive a dividend or other distribution.

On July 5, 2023, and in an
effort to bring our Depositary Share price into compliance with NASDAQ’s minimum bid price per share requirement, we effected a
ratio change in the number of Ordinary Shares represented by our Depositary Shares from five Ordinary Shares per Depositary Share to 400
Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued.

On October 4, 2024, and in
an effort to bring our Depositary Share price into compliance with NASDAQ’s minimum bid price per share requirement, we effected
a ratio change in the number of Ordinary Shares represented by our Depositary Shares from 400 Ordinary Shares per Depositary Share to
10,000 Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued.

On November 22, 2024, we held
a general meeting of shareholders, or November GM, and our shareholders passed resolutions to (i) subdivide our Ordinary Shares of £0.001
nominal value each into one ordinary share of £0.000